Famciclovir and valaciclovir were approved for use in the treatment of herpes zoster despite controversy over antiviral therapy in zoster due to high costs and uncertain benefits. To explore these issues, a Markov decision model was developed, and the incremental cost effectiveness of antiviral treatment for herpes zoster was estimated using these agents compared with no antiviral therapy. A third-party payer perspective was taken. Sensitivity analyses were performed, modeling differences in antiviral efficacy, postherpetic neuralgia (PHN) risk, and other illness parameters. Treatment of severely symptomatic acute zoster was found reasonable from a cost-effectiveness standpoint in base-case and worst-case scenarios. Treatment of mildly symptomatic acute zoster was more expensive but would likely be considered cost effective in scenarios where PHN risk was higher, PHN duration longer, or antiviral shortening of PHN greater. Further research comparing antiviral efficacy in herpes zoster is needed.
Famciclovir and valaciclovir were recently released, joining tients with HZ and to identify the clinical and cost parameters that would most affect the decision to treat with antiviral agents. acyclovir as US Food and Drug Administration -approved drugs for the treatment of herpes zoster (HZ). However, controversy still surrounds antiviral therapy for immunocompetent patients with zoster, due to the relatively high costs and uncerMethods tain benefits from antiviral use [1 -4] . Whether these newer
Using standard decision-analysis computer software (Decision agents offer any clinical advantages over acyclovir for zoster Maker 7.01; Pratt Medical Group, Boston), we developed a Maris unclear [5] .
kov decision model to estimate the incremental cost per qualityAntiviral therapy decreases the severity and duration of acute adjusted life year (QALY) gained by treating HZ patients with zoster symptoms, and all agents seem equally effective for this either famciclovir or valaciclovir compared with no antiviral. We purpose [5] ; however, the effects of antivirals on postherpetic did not compare the drugs to one another due to the lack of direct neuralgia (PHN) are mixed. Several studies using oral acyclovir comparison data. A third-party payer perspective was taken, conshowed inconsistent reduction of PHN [6 -12] . One study sidering only the direct medical costs of illness [16] .
found reduced duration of PHN with famciclovir compared QALYs are derived by multiplying years of life by the qualitywith a placebo [13] , while another showed no reduction in The model. Markov models estimate cost effectiveness by tracking the health states of hypothetical patients over time, and they calculate costs and effectiveness on the basis of time spent in each state of health [17] . Patients may change health states or considered patients to be in one of four health states: with PHN, values not obtained from the literature. Those parameters that, with variation, crossed the $50,000/QALY-gained threshold were then no PHN, hospitalized for acute zoster symptoms, dead due to causes unrelated to zoster (no patients died of zoster or zoster studied in multiway analyses, varying two or more parameters simultaneously. An incremental cost of $50,000/QALY gained is symptoms). The Markov cycle length was 1 month. We assumed that antiviral treatment might shorten the duration of PHN but a commonly used reference point [26, 27] but should not be interpreted as an absolute cost-effectiveness criterion since no such would not modify the probability of its occurrence. Hospitalization was due only to acute zoster symptoms and was not modified by criterion exists [26] . However, in the literature, costs per QALY much above $50,000 are unlikely to be considered cost effective, antiviral treatment. We also assumed that PHN began during the month after HZ onset. Side effects of antiviral therapy were not while costs £$50,000 are typically judged favorably [27] . explicitly modeled, due to their relative rarity and mildness [1, 13- along with the antiviral reduction of PHN duration, using the Discussion $50,000/QALY-gained threshold. For example, if an average
In our analysis, treatment of severely symptomatic acute HZ PHN utility value of 0.85 was used (rather than the baseline cost £$50,000/QALY gained through a broad range of clinical value of 0.9) and the reduction in PHN duration with antiviral and cost parameters. Our study supports recommendations for therapy was 10%, the point denoting those values would fall antiviral treatment of severe acute zoster in patients §50 years within the lightly shaded area on the famciclovir graph in figure old within 72 h of rash onset [5] . Treatment of patients õ50 1. Therefore, the cost per QALY gained for famciclovir treatyears old with severe acute zoster is also recommended [5] ment would be £$50,000 if the risk of PHN was §20%, but and would likely be cost effective on the basis of acute sympthe cost would be ú$50,000 if PHN risk was £10%. Using tom relief alone. It is unclear if antiviral treatment of severe the same values in the valaciclovir graph in figure 1 , that point acute zoster begun ú72 h after rash onset is cost effective, but falls into the unshaded area; therefore the cost per QALY further research in this area is warranted. gained is £$50,000 if PHN risk is §10%.
Treatment of mildly symptomatic acute zoster is more exIn mild acute zoster, famciclovir treatment would always pensive, with cost effectiveness most sensitive to variation of cost £$50,000/QALY gained if it reduced PHN duration by PHN risk, symptom severity during PHN, drug costs, and drug §52.9%, given a PHN utility of £0.95 and a PHN risk of effectiveness in PHN and acute zoster. When a patient presents §10%. If we used the same values, valaciclovir would cost with mild acute zoster, questions should be answered to allow a £$50,000/QALY if it decreased PHN duration by §20.2%.
cost-effective decision to be made regarding the use of antiviral Costs ú$50,000/QALY gained are seen in the hatched area therapy. of each graph in figure 1 . If PHN duration were to be reduced
The first question is whether antiviral drugs change the £4% by famciclovir or £2% by valaciclovir, antiviral treatcourse of PHN and, if they do, which one is most effective? ment of mild acute zoster would cost ú$50,000/QALY, unless Both famciclovir and valaciclovir have shown benefits for pathe probability of PHN was ú30%.
tients with PHN [13, 15] , and acyclovir is probably beneficial If the degree of acute symptom relief were to be substituted also [28, 29] . However, no agent changes the probability or for PHN risk in the multiway analysis, similar areas of cost effectiveness for famciclovir and valaciclovir would be seen. severity of PHN; only the duration is affected [6 -15] rals may reduce PHN duration more than the 20% used in the PHN are needed to allow the best medical decision, which is not necessarily the most frugal one. analysis, with recent data suggesting a 50% reduction [13, 28, 29] . If further studies confirm this, antiviral therapy would
The second question is whether there are clinical characteristics that predict the risk, severity, and duration of PHN in mild likely be considered cost effective in all patients ú50 years old, regardless of acute zoster severity. On the basis of available acute zoster. Patient age is perhaps the best predictor. Age as an independent variable in our analysis was not a sensitive data, one agent cannot be declared superior to another for HZ. Hence, in this increasingly cost-oriented era, drug costs may parameter, but increasing age is known to increase the probability, severity, and duration of PHN [2 -5, 18 -20] . Our model become a major factor in treatment choice. Using average wholesale prices from December 1995, we determined that a suggests that treating mild acute zoster in patients over the age of 70 or 80 would be cost effective because the risk of PHN course of valaciclovir costs Ç$32 less than famciclovir, and the cost of famciclovir ($129.15) was comparable to that for approaches §30% in that age group [2 -5, 18 -20] . The cost effectiveness of treating younger patients, in whom PHN is acyclovir ($128.95) [25] . If no difference in drug effectiveness can be distinguished, the least expensive drug is most cost rarer and less severe, depends more on the effect of treatment on PHN duration. Clarification awaits further investigation, but effective. More and better data comparing antiviral agents in
